Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06136936 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia
A NA study of Schizophrenia, sponsored by Click Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT06136936: Completed NA study of Schizophrenia, sponsored by Click Therapeutics.
NCT06136936 is a NA study of Schizophrenia that has completed, run by Click Therapeutics. The registered enrollment target is 53 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06136936, a NA study of Schizophrenia, has completed, sponsored by Click Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
An exploratory, double-arm, 4-week study to explore the feasibility and acceptability of abbreviated treatment with CT-156 for people with Schizophrenia.
Primary Outcome
Number of days the Study App is opened out of total days of treatment
Conditions Studied
Interventions
- DEVICE CT-156-C-001
Study Locations (1)
New York
- Click Therapeutics - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2023-09-20 |
| Est. Completion | 2024-02-22 |
| Phase | NA |
What the finished NCT06136936 record still lists
NCT06136936 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which CT-156-C-001 is the first listed.
NCT06136936 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06136936 about?
NCT06136936 is a clinical study titled "A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia". An exploratory, double-arm, 4-week study to explore the feasibility and acceptability of abbreviated treatment with CT-156 for people with Schizophrenia.
What is the current status of trial NCT06136936?
This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2023-09-20. Estimated completion is 2024-02-22.
What conditions does trial NCT06136936 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT06136936?
The interventions under investigation include: CT-156-C-001 (DEVICE).
Who is sponsoring clinical trial NCT06136936?
This trial is sponsored by Click Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06136936 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06136936's enrollment target sits among peer trials
53 202nd of 315 higher than 113 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI